We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Flow Cytometry Assay Speeds Diagnosis of Pediatric Tuberculosis

By LabMedica International staff writers
Posted on 14 Sep 2014
Epidemiologists working with samples obtained from groups of children in Tanzania, used a novel blood test to quickly diagnose victims of pediatric tuberculosis (TB).

The diagnosis of pediatric tuberculosis is complicated by nonspecific symptoms, difficult specimen collection, and the low number of organisms usually observed in biopsy specimens.

Investigators at the Swiss Tropical and Public Health Institute (Basel, Switzerland) and colleagues at Ludwigs-Maximilians-Universität (Munich, Germany) worked with samples collected from children with symptoms that suggested tuberculosis who had been prospectively recruited at the NIMR-Mbeya Medical Research Center in Mbeya (Tanzania), and the Ifakara Health Institute in Bagamoyo (Tanzania), between May 10, 2011, and September 4, 2012. More...
Sputum and peripheral blood mononuclear cells were obtained for Mycobacterium tuberculosis culture and for performance assessment of the novel TAM-TB blood test.

The TAM-TB assay is based on flow cytometry detection of loss of the CD27 surface marker usually expressed on CD4+ T-cells. This marker disappears after infection of these cells by M. tuberculosis. Results from this assay are available in about 24 hours as compared to results from culture, which require about 20 days.

Among 290 children screened in this study, the investigators selected a subgroup of 130 to ensure testing of at least 20 with culture-confirmed tuberculosis. Of this group of 130, 17 children were excluded because of inconclusive TAM-TB assay results. The TAM-TB assay enabled detection of 15 of 18 culture-confirmed cases (sensitivity 83.3%). Specificity was 96.8% in the 63 cases that were classified as not tuberculosis, with little effect from latent tuberculosis infection. The TAM-TB assay identified five additional patients with highly probable or probable tuberculosis, in whom M. tuberculosis was not isolated.

"This rapid and reliable test has the great potential to significantly improve the diagnosis of active tuberculosis in children," said contributing author Dr. Klaus Reither, TB CHILD Program Manager at the Swiss Tropical and Public Health Institute.

The study was published in the September 1, 2014, online edition of the journal Lancet Infectious Diseases.

Related Links:
Swiss Tropical and Public Health Institute
Ludwigs-Maximilians-Universität


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
High-Density Lipoprotein Containing Cholesterol Assay
HDL-c direct FS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.